Skip to main content
. 2022 Nov 20;25(11):803–810. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2022.102.47

表 4.

152例免疫联合治疗NSCLC患者LIPI、iSEND免疫评分与PFS的关系

Relationship between LIPI, iSEND immune score and PFS in 152 NSCLC patients treated with combined immunotherapy

Predictive models Group n mPFS (mon) 95%CI
LIPI Good 46 10.7 8.844-12.642
Intermediate 70 5.9 4.293-7.469
Poor 36 4.0 2.497-8.016
iSEND Good 21 11.0 7.385-14.562
Intermediate 105 7.4 5.842-9.008
Poor 26 3.4 2.593-4.175
Total 152 6.6 5.251-8.016